Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Expert Panel
100%
National Lipid Association
100%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
100%
Homozygous Familial Hypercholesterolemia (HoFH)
66%
Low-density Lipoprotein Cholesterol (LDL-C)
66%
Clinical High Risk
33%
Risk Factors
33%
Clinical Utility
33%
Safety Profile
33%
Non-high-density Lipoprotein Cholesterol (non-HDL-C)
33%
Dyslipidemia
33%
Cardiovascular Outcomes
33%
Cardiovascular Disease Events
33%
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
33%
Antibody Therapy
33%
Evidence-based Recommendations
33%
Ultra-high Risk
33%
Polygenic Hypercholesterolemia
33%
Statin Intolerance
33%
Panel Evidence
33%
Patient-centered Management
33%
Biochemistry, Genetics and Molecular Biology
Lipid
100%
Subtilisin
100%
Kexin
100%
Proprotein Convertase
100%
Familial Hypercholesterolemia
66%
Low-Density Lipoprotein
33%
Lipoprotein
33%
Statin
33%
Hypercholesterolemia
33%
Dyslipidemia
33%
Medicine and Dentistry
Proprotein Convertase 9
100%
Familial Hypercholesterolemia
66%
Cardiovascular System
33%
Lipoprotein
33%
Low Density Lipoprotein Cholesterol
33%
Statin
33%
Dyslipidemia
33%
Hypercholesterolemia
33%
Antibody Therapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Coronary Artery Atherosclerosis
100%
Proprotein Convertase 9
100%
Familial Hypercholesterolemia
50%
Lipoprotein
25%
Low Density Lipoprotein Cholesterol
25%
Statin (Protein)
25%
Hypercholesterolemia
25%
Dyslipidemia
25%